News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Grants Intracel Special Protocol Assessment For Confirmatory, Pivotal Phase III Study Of OncoVAX(R) Colon Cancer Vaccine



7/19/2006 11:27:47 AM

FREDERICK, Md.--(BUSINESS WIRE)--July 19, 2006--Intracel, a biotechnology company developing patient-specific cancer immunotherapies, has been granted a special protocol assessment (SPA) by the U.S. Food and Drug Administration (FDA) for the execution of a confirmatory, Phase III clinical trial of OncoVAX, a patient-specific active immunotherapy, in stage II colon carcinoma. An SPA provides a mechanism for the FDA and sponsors to reach agreement on the design, size, execution and analysis of a clinical trial that is intended to form the primary basis for regulatory approval.

Read at press release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES